Samsung Biologics makes $1.8 billion all-cash offer for Switzerland’s PolyPeptide Group

 South Korea’s Samsung Biologics said on Monday that it had made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland’s PolyPeptide Group.